US Archives - Page 127 of 147 - European Medical Journal

What’s the Link Between Traumatic Brain Injury and Alzheimer's?

Traumatic brain injury accounts for 30% of all injury-related deaths in the United States, and is a major cause of death and disability in the country.

Personalized Immunotherapy for Resistant Lung Cancer Mutations

A new study from The University of Texas MD Anderson Cancer Center has revealed that a combination of dual immunotherapy and chemotherapy improves outcomes for patients with metastatic NSCLC who harbor specific mutations.

New Research in HSV-2 Recurrence Therapy

HSV-1 and HSV-2 establish latent/reactivation patterns, giving rise to recurrent epithelial lesions, cold sores and genital herpes, in patients. These persistent infections have affected over half of the US adult population yet the pathogenic mechanism is not well understood.

Game-Changing Approach to Glioblastoma Treatment

A promising treatment strategy for glioblastoma has been unveiled in a significant breakthrough that addresses the urgent need for effective therapeutic options.

How is Addison’s Disease Managed?

Addison’s disease is a rare but serious endocrine disorder, which presents unique challenges for healthcare providers.

Understanding Complications of Metabolically Healthy Obesity: CHEST 2024

A nationwide study presented at the CHEST Annual Meeting 2024 revealed rising trends in metabolically healthy obesity (MHO) among elderly patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease

Neighborhood Disadvantages Increase Lung Disease Rates: CHEST 2024

A strong link has been identified between the cumulative impact of neighborhood-level environmental and social factors, known as the “neighborhood exposome,” and the prevalence of asthma and COPD in U.S. adults

New Score Predicts Clinical Outcomes in MAC Lung Disease: CHEST 2024

A new study has shown that the BACES score, a clinical tool used to predict mortality in non-tuberculous mycobacteria (NTM) lung disease, can also help predict treatment outcomes in patients with Mycobacterium avium complex lung disease (MAC-LD)

AI Breakthrough in Pulmonary Hypertension Diagnosis: CHEST 2024

Pulmonary hypertension is a progressive and potentially fatal condition that can go undetected until it reaches advanced stages. A groundbreaking study presented at the CHEST Annual Meeting 2024 introduces a multimodal fusion model (MMF-PH) that incorporates AI

Dupilumab for COPD Phase 3 Trial Results: CHEST 2024

Findings from two Phase 3 clinical trials, BOREAS and NOTUS, revealed that dupilumab, a monoclonal antibody targeting key drivers of type 2 inflammation, improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD)